PBLA — Panbela Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Panbela Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Panbela Receives Approvals To Open Trial Sites In Spain, France And Italy For Aspire Trial Studying Ivospemin (Sbp-101) In Combination With Gemcitabine And NAB-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Brief: Panbela Therapeutics Inc Files For Public Offering Of 28.9 Million Shares Of Common Stock And Common Stock Purchase Warrants - SEC Filing
Brief: Panbela Therapeutics Inc Says On Aug 19, Co Received A Letter From Nasdaq Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Panbela Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Panbela Reports Q2 2022 Financial Results
Panbela Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Panbela Therapeutics Enters Into Sales Agreement With Roth Capital Partners
Brief: Panbela Announces Publication Of Preclinical Data Titled Expanded Potential Of The Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) As A Modulator Of Polyamine Metabolism And Cancer Therapeutic
Panbela Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Panbela Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Panbela Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Panbela Provides Business Update And Reports Q4 And FY 2021 Financial Results
Panbela Therapeutics Inc expected to post a loss of 18cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Homology Medicines, Meritor Inc, FAT Brands
Panbela Therapeutics jumps on deal to buy private drug developer
Brief: Panbela Therapeutics To Acquire Cancer Prevention Pharmaceuticals
NASDAQ RESUMED AT 08:30 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM